Prevention of insult with nondirective anticoagulant therapy by warfarin (warfarex) in patients with atrial fibrillation

The aim of the study was to estimate efficiency and safety of treatment by non-direct anticoagulant--warfarex in the patients with persistent and paroxysmal forms of AF for the prevention of thromboembolic complications. 55 patients between 37 and 75 years old with atrial fibrillation (AF) were investigated. Follow-up was 2 years. Primary diseases were post myocardic cardiosclerosis, cardiomyopathy, IHD, arterial hypertension. The patients with persistent form of AF underwent treatment by warfarex. In the case of paroxysmal form of AF patients were prescribed warfarex during the first 48 hours from the beginning of paroxysm and for 3-4 weeks after cardioversion. The dose of warfarex was chosen according International Normalized Ratio (2.0-3.0). The results of the study show, that warfarex is effective and safe for the prevention of thromboembolic complications in the case of persistent and paroxysmal forms of AF.